# Palliative Short-course Hypofractionated Radiotherapy Followed by Chemotherapy in Adenocarcinoma of the Esophagus or Esophagogastric Junction Trial - a Phase II Clinical Trial Protocol.

> **NCT02241499** · PHASE2 · COMPLETED · sponsor: **Lund University Hospital** · enrollment: 29 (actual)

## Conditions studied

- Adenocarcinoma of the Esophagus or Esophagogastric Junction

## Interventions

- **RADIATION:** Radiation therapy
- **DRUG:** Oxaliplatin and fluorouracil.

## Key facts

- **NCT ID:** NCT02241499
- **Lead sponsor:** Lund University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2019-05
- **Final completion:** 2019-05
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2020-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02241499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02241499, "Palliative Short-course Hypofractionated Radiotherapy Followed by Chemotherapy in Adenocarcinoma of the Esophagus or Esophagogastric Junction Trial - a Phase II Clinical Trial Protocol.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02241499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*